Insider Purchases: Inside the Buy
Tag: Genomics
🧬 Absci (ABSI): A Director Bought After a 5× Rally. Here's Why the Story May Still Be in Its Early Innings.
When FUNanc1al first highlighted Absci around $4.18, the thesis centered on insider buying and an overlooked AI-biotech platform. Today the stock has nearly tripled, Eli Lilly has invested $100 million, institutions own over 80%, and another director is buying shares. Here's why the story may still be in its early innings.
🔬 Illumina (ILMN): Let’s Illuminate the Bull Case!
After losing nearly 80% of its value since 2021, Illumina (ILMN) may be ready for a glow-up. CEO Jacob Thaysen and CFO Ankur Dhingra just bought big, and institutional holders are still hanging on. What do they see—and should you see it too?
🧬 GeneDx (WGS): Profit, Progress, and a 43% Plunge? Sounds Genetic.
GeneDx is profitable. Revenues are growing. Innovation is real. So why did the stock tank 43%? Here’s your deep-dive into the DNA of a biotech rollercoaster—with humor, icons, and a whole lot of exome.